Ascletis Receives FDA Clearance to Begin Phase I Trial of Once-Monthly Obesity Peptide ASC35

Ascletis Pharma has announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application for ASC35, paving the way for a Phase I clinical trial in the United States. ASC35 is a dual agonist peptide designed to activate both the GLP-1 receptor and the GIP receptor, two pathways that have become central to modern approaches for weight management and metabolic health.

What makes ASC35 particularly noteworthy is its once-monthly subcutaneous dosing schedule. Many currently available GLP-1-based therapies require weekly injections, so a treatment that could maintain efficacy with monthly administration may offer a meaningful convenience advantage for patients seeking long-term obesity management. Reduced dosing frequency has the potential to support easier treatment adherence, which is often a key factor in the long-term success of chronic disease management programs.

The clearance of the IND application represents an important regulatory milestone, allowing Ascletis to move ASC35 from preclinical research into human testing. Phase I trials typically focus on evaluating safety, tolerability, and pharmacokinetics in a small group of participants, laying the groundwork for larger studies that would further assess effectiveness in the target patient population.

The dual-agonist approach targeting both GLP-1 and GIP receptors builds on a growing body of scientific interest in incretin-based therapies for metabolic conditions. By engaging two complementary hormonal pathways, dual agonists like ASC35 aim to build on the therapeutic strategies already showing promise in the obesity treatment space, potentially broadening the range of options available to patients and physicians in the future.

As this Phase I study gets underway, the peptide therapeutics field continues to see steady progress toward more convenient and effective options for individuals managing obesity. Continued clinical development will be needed to determine how ASC35 performs in terms of safety and effectiveness, but this regulatory clearance marks an encouraging step forward in that process. This article is for informational purposes only and is not medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Ascletis Announces U.S. FDA IND Clearance for Phase I Study of Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for the Treatment of Obesity – PR Newswire